EA201001204A1 - Методы и композиции, в которых применяют слитые полипептиды klotho-fgf - Google Patents
Методы и композиции, в которых применяют слитые полипептиды klotho-fgfInfo
- Publication number
- EA201001204A1 EA201001204A1 EA201001204A EA201001204A EA201001204A1 EA 201001204 A1 EA201001204 A1 EA 201001204A1 EA 201001204 A EA201001204 A EA 201001204A EA 201001204 A EA201001204 A EA 201001204A EA 201001204 A1 EA201001204 A1 EA 201001204A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- klotho
- compositions
- methods
- apply
- polypeptides fused
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000015834 Klotho Human genes 0.000 abstract 3
- 108050004036 Klotho Proteins 0.000 abstract 3
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01031—Beta-glucuronidase (3.2.1.31)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
В заявке описаны способы, наборы и композиции, предназначенные для предупреждения или лечения связанных с возрастом состояний или метаболических нарушений. Слитые полипептиды Klotho, предлагаемые в изобретении, включают по меньшей мере белок Klotho или его активный фрагмент. Слитые белки Klotho можно применять для лечения и предупреждения различных связанных с возрастом состояний и метаболических нарушений.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6301508P | 2008-01-28 | 2008-01-28 | |
PCT/EP2009/050850 WO2009095372A1 (en) | 2008-01-28 | 2009-01-26 | Methods and compositions using klotho-fgf fusion polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201001204A1 true EA201001204A1 (ru) | 2011-02-28 |
Family
ID=40492768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201001204A EA201001204A1 (ru) | 2008-01-28 | 2009-01-26 | Методы и композиции, в которых применяют слитые полипептиды klotho-fgf |
Country Status (21)
Country | Link |
---|---|
US (2) | US8481031B2 (ru) |
EP (1) | EP2247614B1 (ru) |
JP (1) | JP5627469B2 (ru) |
KR (1) | KR20100118126A (ru) |
CN (1) | CN102015760B (ru) |
AR (1) | AR070690A1 (ru) |
AU (1) | AU2009209696B2 (ru) |
BR (1) | BRPI0906722A2 (ru) |
CA (2) | CA2854933A1 (ru) |
CL (1) | CL2009000166A1 (ru) |
CO (1) | CO6300826A2 (ru) |
CR (1) | CR11580A (ru) |
EA (1) | EA201001204A1 (ru) |
EC (1) | ECSP10010372A (ru) |
ES (1) | ES2479417T3 (ru) |
IL (1) | IL207161A0 (ru) |
MA (1) | MA32031B1 (ru) |
MX (1) | MX2010008206A (ru) |
PE (1) | PE20091405A1 (ru) |
TW (1) | TW200936156A (ru) |
WO (1) | WO2009095372A1 (ru) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2675514C2 (ru) * | 2012-12-27 | 2018-12-19 | ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. | Способы модуляции гомеостаза желчных кислот и лечение расстройств и заболеваний, ассоциированных с желчными кислотами |
US10369199B2 (en) | 2013-10-28 | 2019-08-06 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of cancer |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
US10413590B2 (en) | 2011-07-01 | 2019-09-17 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants of FGF19 polypeptides for reducing body mass in a subject |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US10517929B2 (en) | 2014-10-23 | 2019-12-31 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising FGF19 variants |
US10744185B2 (en) | 2015-11-09 | 2020-08-18 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of pruritus |
US10758590B2 (en) | 2012-11-28 | 2020-09-01 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF 19 polypeptides for treating diabetes |
US11066454B2 (en) | 2012-11-28 | 2021-07-20 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
US11103554B2 (en) | 2012-12-27 | 2021-08-31 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants of FGF19 polypeptides for reducing bile acid synthesis in a subject having cirrhosis |
US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
US8420088B2 (en) * | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
UA105016C2 (ru) | 2008-10-10 | 2014-04-10 | Амген Інк. | Fgf21 мутанты и их применение |
KR101860572B1 (ko) | 2009-05-05 | 2018-05-24 | 암젠 인크 | Fgf21 돌연변이체 및 이의 용도 |
EP2427207B1 (en) | 2009-05-05 | 2017-08-16 | Amgen, Inc | Fgf21 mutants and uses thereof |
CA2764835A1 (en) * | 2009-06-17 | 2010-12-23 | Amgen Inc. | Chimeric fgf19 polypeptides and uses thereof |
US8535912B2 (en) * | 2009-10-15 | 2013-09-17 | Genentech, Inc. | Chimeric fibroblast growth factors with altered receptor specificity |
US8889621B2 (en) | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
EP2506861A1 (en) * | 2009-12-02 | 2012-10-10 | Amgen Inc. | Binding proteins that bind to human fgfr1c, human b-klotho and both human fgfr1c and human b-klotho |
UA109888C2 (uk) * | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
CA2783555A1 (en) | 2009-12-16 | 2011-07-14 | Eli Lilly And Company | Therapeutic uses of soluble alpha-klotho |
JP2013523184A (ja) | 2010-04-15 | 2013-06-17 | アムジエン・インコーポレーテツド | ヒトFGF受容体およびβ−KLOTHO結合性タンパク質 |
EP2571510B1 (en) * | 2010-05-21 | 2018-08-08 | XL-protein GmbH | Biosynthetic proline/alanine random coil polypeptides and their uses |
HUE055963T2 (hu) * | 2010-06-25 | 2022-01-28 | Shire Human Genetic Therapies | Eljárások és kompozíciók iduronát-2-szulfáz központi idegrendszerbe történõ leadásához |
CN102465182A (zh) * | 2010-10-29 | 2012-05-23 | 株式会社爱茉莉太平洋 | 检测皮肤活性物质的检测试剂盒和检测皮肤活性物质的方法 |
WO2013027191A1 (en) * | 2011-08-25 | 2013-02-28 | Novartis Ag | Methods and compositions using fgf23 fusion polypeptides |
TWI478002B (zh) * | 2012-02-09 | 2015-03-21 | Univ Nat Sun Yat Sen | 一種篩選治療或預防帕金森氏症及其併發症之候選藥物的方法 |
US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
JP6159930B2 (ja) * | 2013-10-24 | 2017-07-12 | 地方独立行政法人東京都健康長寿医療センター | 筋幹細胞又は筋芽細胞、及びそれを用いた代謝変換に関与する物質のスクリーニング方法、並びにスクリーニング方法によって得られた物質を含む医薬組成物 |
ES2808340T3 (es) | 2014-01-24 | 2021-02-26 | Ngm Biopharmaceuticals Inc | Anticuerpos que se unen al dominio de beta klotho 2 y procedimientos de uso de los mismos |
AU2015237176A1 (en) * | 2014-03-28 | 2016-10-20 | New York University | FGF23 fusion proteins |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
WO2016088059A1 (en) * | 2014-12-04 | 2016-06-09 | Novartis Ag | Methods and compositions using klotho variant polypeptides |
CN105838661B (zh) * | 2014-12-30 | 2020-11-10 | 深圳市第二人民医院 | Klotho基因编辑在异种肾脏移植中的应用 |
CN107405382A (zh) * | 2015-02-06 | 2017-11-28 | 加利福尼亚大学董事会 | 用于改善认知的方法和组合物 |
EP3262159B1 (en) * | 2015-02-27 | 2019-07-24 | Apceth GmbH & Co. KG | Genetically modified mesenchymal stem cell expressing klotho |
WO2017008016A1 (en) * | 2015-07-09 | 2017-01-12 | The Board Of Regents Of The University Of Texas System | Nanoparticles containing extracellular matrix for drug delivery |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
KR102570250B1 (ko) * | 2016-06-02 | 2023-08-29 | 클로토 테라퓨틱스, 아이엔씨. | 치료학적 재조합 클로토 단백질 및 이를 수반하는 조성물 및 방법 |
KR20230093531A (ko) * | 2016-11-22 | 2023-06-27 | 클로토 테라퓨틱스, 아이엔씨. | 신규한 재조합 클로토 단백질 및 이를 수반하는 조성물 및 방법 |
CA3069143A1 (en) | 2017-07-06 | 2019-01-10 | Yale University | Compositions and methods for treating or preventing endocrine fgf-linked diseases |
EP3720474A4 (en) * | 2017-12-06 | 2021-12-29 | Klotho Therapeutics, Inc. | Products and methods for assessing and increasing klotho protein levels |
AU2018384735A1 (en) * | 2017-12-13 | 2020-06-25 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating or preventing endocrine FGF23-linked diseases |
CN108434441A (zh) * | 2018-04-17 | 2018-08-24 | 哈尔滨博翱生物医药技术开发有限公司 | 新型成纤维细胞生长因子-21类似物在治疗弥漫性间质性肺脏疾病中的应用 |
CN109722480B (zh) * | 2018-05-17 | 2022-04-26 | 上海交通大学 | 一种非小细胞肺癌检测试剂盒及其应用 |
US11969460B2 (en) | 2018-06-08 | 2024-04-30 | Saint Louis University | Methods and compositions for treating decreased cognitive ability |
US11891615B2 (en) | 2020-06-10 | 2024-02-06 | Gail Marion Humble | Process to produce Klotho protein in vitro |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US853A (en) | 1838-07-24 | Jesse reed | ||
US6406A (en) | 1849-05-01 | Artificial teeth | ||
IL71691A (en) | 1984-04-27 | 1991-04-15 | Yeda Res & Dev | Production of interferon-ypsilon |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
US5266561A (en) | 1988-01-11 | 1993-11-30 | Amylin Pharmaceuticals, Inc. | Treatment of type 2 diabetes mellitus |
EP0550436A1 (en) | 1989-11-06 | 1993-07-14 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
ES2217250T3 (es) | 1990-06-15 | 2004-11-01 | Scios Inc. | Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer. |
US5408038A (en) * | 1991-10-09 | 1995-04-18 | The Scripps Research Institute | Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5420112A (en) | 1992-06-12 | 1995-05-30 | Lewis; Michael E. | Prevention and treatment of peripheral neuropathy |
US5541094A (en) * | 1992-09-25 | 1996-07-30 | E. I. Du Pont De Nemours And Company | Glyoxylic acid/aminomethylphosphonic acid mixtures prepared using a microbial transformant |
US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
US6187992B1 (en) | 1994-12-05 | 2001-02-13 | Merck & Co., Inc. | Transgenic mouse having a disrupted amyloid precursor protein gene |
WO1997007788A2 (en) | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
US6194177B1 (en) | 1996-02-20 | 2001-02-27 | Applied Research Systems Ars Holding N.V. | DNA encoding a hybrid heterodimeric protein |
JP3258027B2 (ja) | 1996-03-15 | 2002-02-18 | サマーセット・ファーマシューティカルズ・インコーポレイテッド | セレジリン投与による末梢ニューロパシーの予防および治療方法 |
US6358752B1 (en) | 1996-09-27 | 2002-03-19 | Cornell Research Foundation, Inc. | Liposome-enhanced test device and method |
AU739057B2 (en) | 1996-12-26 | 2001-10-04 | Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. | Novel polypeptide, novel DNA, and novel antibody |
US6127598A (en) | 1997-07-25 | 2000-10-03 | The Regents Of The University Of California | NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression, and obesity |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
WO1999051773A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
US7060479B2 (en) * | 1999-12-08 | 2006-06-13 | Serono Genetics Institute, S.A. | Full-length human cDNAs encoding potentially secreted proteins |
US20030055231A1 (en) | 1998-10-28 | 2003-03-20 | Jian Ni | 12 human secreted proteins |
CA2367820C (en) | 1999-04-22 | 2009-12-22 | James D. Otvos | Nmr-method for determining the risk of developing type 2 diabetes |
US6569832B1 (en) | 1999-11-12 | 2003-05-27 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
US20060160181A1 (en) * | 2000-02-15 | 2006-07-20 | Amgen Inc. | Fibroblast Growth Factor-23 molecules and uses thereof |
EP2075255A1 (en) | 2000-03-08 | 2009-07-01 | Novartis Vaccines and Diagnostics, Inc. | Human FGF-23 gene and gene expression products |
EP1303536B1 (en) | 2000-07-19 | 2010-03-17 | Advanced Research And Technology Institute, Inc. | Novel fibroblast growth factor (fgf23) and methods for use |
EP1425289A4 (en) | 2001-01-30 | 2004-10-13 | Regeneron Pharma | NOVEL NUCLEIC ACID AND POLYPEPTIDE MOLECULES |
US7588757B2 (en) | 2001-03-14 | 2009-09-15 | Genzyme Corporation | Methods of treating Parkinson's disease using recombinant adeno-associated virus virions |
US7217798B2 (en) | 2003-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of Fc-fusion protein serum half-lives by mutagenesis |
JP2006240990A (ja) * | 2003-05-15 | 2006-09-14 | Kirin Brewery Co Ltd | klothoタンパク質および抗klothoタンパク質抗体ならびにそれらの用途 |
JP2006158339A (ja) * | 2004-12-09 | 2006-06-22 | Kyoto Univ | βKlotho遺伝子、Cyp7a1遺伝子、及びそれらの利用 |
US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
WO2009117622A2 (en) | 2008-03-19 | 2009-09-24 | Ambrx, Inc. | Modified fgf-23 polypeptides and their uses |
UA105016C2 (ru) | 2008-10-10 | 2014-04-10 | Амген Інк. | Fgf21 мутанты и их применение |
EP2427207B1 (en) | 2009-05-05 | 2017-08-16 | Amgen, Inc | Fgf21 mutants and uses thereof |
US8461111B2 (en) | 2009-05-20 | 2013-06-11 | Florida State University Research Foundation | Fibroblast growth factor mutants having improved functional half-life and methods of their use |
US20110195077A1 (en) | 2010-01-29 | 2011-08-11 | Novartis Ag | Methods and compositions using fgf23 fusion ppolypeptides |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
-
2009
- 2009-01-22 TW TW098102662A patent/TW200936156A/zh unknown
- 2009-01-26 ES ES09706624.5T patent/ES2479417T3/es active Active
- 2009-01-26 CA CA2854933A patent/CA2854933A1/en not_active Abandoned
- 2009-01-26 EA EA201001204A patent/EA201001204A1/ru unknown
- 2009-01-26 JP JP2010543520A patent/JP5627469B2/ja not_active Expired - Fee Related
- 2009-01-26 KR KR1020107019047A patent/KR20100118126A/ko not_active Application Discontinuation
- 2009-01-26 WO PCT/EP2009/050850 patent/WO2009095372A1/en active Application Filing
- 2009-01-26 AU AU2009209696A patent/AU2009209696B2/en not_active Ceased
- 2009-01-26 MX MX2010008206A patent/MX2010008206A/es active IP Right Grant
- 2009-01-26 CA CA2712634A patent/CA2712634C/en not_active Expired - Fee Related
- 2009-01-26 CN CN200980111072.0A patent/CN102015760B/zh not_active Expired - Fee Related
- 2009-01-26 EP EP09706624.5A patent/EP2247614B1/en active Active
- 2009-01-26 BR BRPI0906722-1A patent/BRPI0906722A2/pt not_active IP Right Cessation
- 2009-01-27 CL CL2009000166A patent/CL2009000166A1/es unknown
- 2009-01-27 AR ARP090100247A patent/AR070690A1/es unknown
- 2009-01-27 PE PE2009000108A patent/PE20091405A1/es not_active Application Discontinuation
- 2009-01-28 US US12/360,970 patent/US8481031B2/en not_active Expired - Fee Related
-
2010
- 2010-07-19 MA MA33039A patent/MA32031B1/fr unknown
- 2010-07-21 CR CR11580A patent/CR11580A/es not_active Application Discontinuation
- 2010-07-22 IL IL207161A patent/IL207161A0/en unknown
- 2010-07-28 EC EC2010010372A patent/ECSP10010372A/es unknown
- 2010-07-28 CO CO10092102A patent/CO6300826A2/es not_active Application Discontinuation
-
2013
- 2013-05-29 US US13/904,574 patent/US9458209B2/en active Active
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10413590B2 (en) | 2011-07-01 | 2019-09-17 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants of FGF19 polypeptides for reducing body mass in a subject |
US11065302B2 (en) | 2011-07-01 | 2021-07-20 | Ngm Biopharmaceuticals, Inc. | Compositions comprising fusion variants of FGF19 polypeptides |
US10758590B2 (en) | 2012-11-28 | 2020-09-01 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF 19 polypeptides for treating diabetes |
US11066454B2 (en) | 2012-11-28 | 2021-07-20 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
RU2675514C2 (ru) * | 2012-12-27 | 2018-12-19 | ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. | Способы модуляции гомеостаза желчных кислот и лечение расстройств и заболеваний, ассоциированных с желчными кислотами |
US11564972B2 (en) | 2012-12-27 | 2023-01-31 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants of FGF19 polypeptides for treating primary biliary cirrhosis in a subject |
US11103554B2 (en) | 2012-12-27 | 2021-08-31 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants of FGF19 polypeptides for reducing bile acid synthesis in a subject having cirrhosis |
US10369199B2 (en) | 2013-10-28 | 2019-08-06 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of cancer |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
US11241481B2 (en) | 2014-06-16 | 2022-02-08 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US10517929B2 (en) | 2014-10-23 | 2019-12-31 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising FGF19 variants |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
US11141460B2 (en) | 2014-11-07 | 2021-10-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
US10744185B2 (en) | 2015-11-09 | 2020-08-18 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of pruritus |
US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
Also Published As
Publication number | Publication date |
---|---|
MX2010008206A (es) | 2010-08-10 |
CA2712634A1 (en) | 2009-08-06 |
ECSP10010372A (es) | 2010-08-31 |
CA2712634C (en) | 2014-09-16 |
AU2009209696A1 (en) | 2009-08-06 |
US9458209B2 (en) | 2016-10-04 |
EP2247614A1 (en) | 2010-11-10 |
CL2009000166A1 (es) | 2010-12-24 |
AU2009209696B2 (en) | 2012-04-19 |
CA2854933A1 (en) | 2009-08-06 |
AR070690A1 (es) | 2010-04-28 |
US8481031B2 (en) | 2013-07-09 |
CO6300826A2 (es) | 2011-07-21 |
BRPI0906722A2 (pt) | 2015-07-07 |
US20130324458A1 (en) | 2013-12-05 |
CR11580A (es) | 2010-10-05 |
EP2247614B1 (en) | 2014-04-09 |
PE20091405A1 (es) | 2009-10-07 |
MA32031B1 (fr) | 2011-01-03 |
IL207161A0 (en) | 2010-12-30 |
WO2009095372A1 (en) | 2009-08-06 |
CN102015760A (zh) | 2011-04-13 |
TW200936156A (en) | 2009-09-01 |
CN102015760B (zh) | 2014-06-11 |
JP5627469B2 (ja) | 2014-11-19 |
ES2479417T3 (es) | 2014-07-24 |
KR20100118126A (ko) | 2010-11-04 |
US20090192087A1 (en) | 2009-07-30 |
JP2011510620A (ja) | 2011-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201001204A1 (ru) | Методы и композиции, в которых применяют слитые полипептиды klotho-fgf | |
EA201201047A1 (ru) | Способы и композиции, в которых применяют слитые полипептиды fgf 23 | |
EA201100062A1 (ru) | Соединения и способы модулирования рецепторов, связанных с белком g | |
EA200870185A1 (ru) | Комбинации ингибиторов ang2 и vegf | |
EA201170349A1 (ru) | Модуляторы mif | |
EA201291138A1 (ru) | Способы, композиции и наборы для лечения нарушений, связанных с минерализацией матрикса | |
EA200971077A1 (ru) | Гетероциклические модуляторы киназы | |
EA201990619A1 (ru) | Fgf21 мутанты и их применение | |
EA201892548A1 (ru) | Антитела к альфа-синуклеину и их применение | |
EA201290209A1 (ru) | Новые модуляторы бензопиран киназы | |
EA200801679A1 (ru) | Композиции и способы применения антител к dickkopf-1 и/или -4 | |
PH12019500596A1 (en) | Recombinant binding proteins and their use | |
EA201290131A1 (ru) | Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний | |
EA201100072A1 (ru) | Новые композиции и способы | |
EA201390803A1 (ru) | Ингибиторы бромодомена и их применение | |
WO2013058833A8 (en) | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof | |
MX2021006017A (es) | Polipeptidos de folistatina y sus usos. | |
EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
EA201270758A1 (ru) | Мутанты fgf21 и их применение | |
EA201100070A1 (ru) | Туберкулезный белок rv2386c, композиции и их применения | |
MY149630A (en) | Antibodies against amyloid-beta peptide | |
EA200800667A1 (ru) | Аптамеры, связывающие тромбин с высокой аффинностью | |
WO2010130830A3 (en) | Anti-sclerostin vhh and their use for treating bone diseases | |
BR112015020235A2 (pt) | fragmento biologicamente ativo de proteína csf-1 ou um seu homólogo, ácido nucléico, proteína de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de realização da proteína de fusão do primeiro aspeto da invenção, composição, utilização de uma proteína de fusão, método de tratamento para um indivíduo sofrendo de cancro do fígado e que irá ser submetido a cirurgia, método de tratamento para um indivíduo que irá ser submetido a cirurgia de transplante de fígado, e, kit |